Danofloxacin-d3 mesylate
Danofloxacin-d3 (mesylate) is the deuterium labeled Danofloxacin mesylate. Danofloxacin mesylate (CP 76136-27) is a fluoroquinolone antibacterial for veterinary use.
For research use only. We do not sell to patients.
- CAS No.: 1217860-94-0
- Formula: C20H21D3FN3O6S
- Molecular Weight:456.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Antibiotic Isoforms
More
Biological Activity
Description
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1217860-94-0
-
Unlabeled CAS 119478-55-6
-
Molecular Weight 456.50
-
Formula C20H21D3FN3O6S
-
SMILES
CS(=O)(O)=O.O=C1C2=CC(F)=C(N3[C@H]4C[C@H](N(C4)C([2H])([2H])[2H])C3)C=C2N(C5CC5)C=C1C(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Giles, C.J., et al., Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J Vet Pharmacol Ther, 1991. 14(4): p. 400-10. [Content Brief]
[3]. McGuirk, P.R., et al., Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine. J Med Chem, 1992. 35(4): p. 611-20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Danofloxacin-d3 mesylate Related Classifications
HY-B0501S Related Classifications
Powered by Bioz